Co-Authors
This is a "connection" page, showing publications co-authored by GREGORY N FULLER and SHOUHAO ZHOU.
Connection Strength
0.264
-
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
Score: 0.046
-
Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019 01 02; 129(1):137-149.
Score: 0.042
-
Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. 2018; 7(4):e1412909.
Score: 0.039
-
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66.
Score: 0.035
-
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016; 1(2).
Score: 0.034
-
Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. Oncoimmunology. 2016 May; 5(5):e1117739.
Score: 0.034
-
MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol. 2016 05; 18(5):639-48.
Score: 0.034